35results about How to "High antigen purity" patented technology

The invention discloses a genetic engineering subunit vaccine for a porcine circovirus as well as a preparation method and application of the genetic engineering subunit vaccine. By cloning the nucleocapsid protein of the novel porcine circovirus 3 (PCV3), a PCV-Cap protein with higher purity is successfully expressed by using an escherichia coli or baculovirus expression system. The subunit vaccine for the PCV3 is successfully developed for the first time by using the PCV-Cap protein; the prepared vaccine is high in antigen purity, good in safety and strong in immunogenicity, and has no pathogenicity to pigs and other animals; the antigen has good solubility in a neutral PH buffer solution; furthermore, the preparation method is simple and low in cost, thus being suitable for large-scaleindustrial production; an effective and powerful means is provided for the prevention and control of novel PCV, and the genetic engineering subunit vaccine has a wide application prospect in the fieldof the prevention and control of the PCV3.

The invention relates to a separation and purification method for a recombinant hepatitis B core antigen. The method includes the steps of thermal denaturation and clarification; ammonium sulfate precipitation; ultrafiltration and concentration, washing filtering and liquid exchange; depolymerization; first-step molecular sieve chromatography; ultrafiltration and concentration, washing filtering and liquid exchange; repolymerization; second-step chromatography. By means of the method, the high-purity, low-host-residue and high-stability recombinant hepatitis B core antigen with a uniform granular structure can be obtained, that is to say, the method has the advantages that the antigen purity is high, the residue of host protein and host nucleic acid is low, antigen particles are uniform, and industrial enlargement is easy.

The invention discloses the sequence of a specific B cell epitope polypeptide of an NS1 protein of encephalitis B virus and the use of the epitope polypeptide in the diagnosis of encephalitis B virus and a screening method of specific B cell epitope polypeptide of NS1 protein of encephalitis B virus, and belongs to the field of molecular immunology. The amino sequence of the epitope polypeptide is represented by SEQ ID No.1 or SEQ ID No.2. The specific B cell epitope synthetic polypeptide of the JEV NS1 protein, the coupling antigen of the synthetic epitope polypeptide and the epitope fusion expression protein can be used for specifically detecting a JEV NS1 protein antibody generated in body which is immunized and infected. The epitope polypeptide can be used for diagnosis of JEV infection, evaluation on immunity effect and identification and diagnosis of immunity of inactivated vaccine and natural infection.

The invention discloses a foot and mouth disease virus-like particle vaccine and a preparation method thereof. By expressing P12A (three amino acid site mutation, VP1K210E, VP1E83K and VP1C134S) and serum-free suspension culture, a virus-like particle (VLP) standard similar to natural 75S FMDV is built, and VLP yield is increased. The invention further provides serum-free suspension cultured and high pH tamed insect cells, the insect cells can stably and efficiently produce FMDV VLP, the size and structure of the VLP produced by the insect cells is similar to those of the VLP produced by standard BHK-21, and the yield of the VLP produced by the insect cells is 11 times of that of the VLP produced by female parent cells Sf21. The vaccine prepared by the VLP produced by the insect cells can immunize animals to generate IgG antibody response. The IgG antibody titer, foot and mouth disease virus neutralizing antibody titer and antibody titer of immunization of the VLP vaccine produced by the insect cells are not evidently different from those of immunization of the VLP vaccine prepared by the BHK-21, so that the high-pH-adaptive insect cells are applicable to FMDV VLP vaccine production.

A dual-antibody sandwith ELISA detecting method for human soluble p185HER-2 antigen features that the purified and coated P185HER-2 monoclonal antibody is bound to solid supporter, the specimen containing soluble p185HER-2, the purified standard p185HER-2 antigen and the coated antibody are incubated, and another purified and coated p185HER-2 monoclonal antibody marked by horseradish perioxidase is used as detecting antibody. It can be used for serum diagnosis of tumor.

The invention provides a porcine circovirus II antibody detection ELISA kit. The kit comprises an ELISA plate coated with a purified escherichia coli-expressed porcine circovirus II Cap protein as an antigen, positive contrast serum, negative contrast serum, a sample diluent, an enzyme labeling conjugate, a washing solution, a substrate solution A, a substrate solution B and a stopping solution. An indirect ELISA method is adopted, the coated plate is coated with the prokaryotic expressed Cap protein as an antigen and antigen purity is high. The ELISA detection kit prepared from the coated plate with the antigen has high sensitivity, specificity and repeatability.

The invention provides a preparation method of a rabies inactivation vaccine for livestock and a stabilizing agent contained in the vaccine. According to the preparation method, a virus concentrationprocess is that (1) a virus supernate continuously penetrates through a 300 KD membrane bag at the flow speed of 0.8-1 L/min, the virus is concentrated until the volume of the virus is 1/50-1/40 of the original volume, and coarse concentration liquid is obtained; (2) a PBS solution with the volume 10-15 times larger than that of the coarse concentration liquid is added into the coarse concentration liquid, the mixture penetrates through the 300 KD membrane bag at the flow speed of 1.8-2 L/min under the concentration pressure of 0.5-1.0 bar, under the condition that the mixture is concentrateduntil the volume of the mixture is 1/4-2/5 of the original volume of the mixture before penetration, the flow speed is adjusted to 0.8-1 L/min, and continuous concentration is conducted until the volume of the mixture is the same as the original volume of the coarse concentration liquid. According to the preparation method, by optimizing the virus concentration process, different membrane-penetration flow speeds are adopted for different antigen concentrations, in the concentration process, 30-50% of impure protein can be removed, the virus titer is kept at 90% or above, and the prepared vaccine is more stable and more efficient.

The invention provides a method for preparing a pig porcine reproductive and respiratory syndrome inactivated vaccine. Through steps of virus clarification, concentration, molecular sieve chromatography, inactivation, freeze-drying and the like, the method is capable of effectively ensuring that the content of impurities in antigen for preparing the vaccine is reduced to the minimum extent, so that the phenomenon that side effects are caused after the product is used can be avoided, and meanwhile the inactivation effect of the vaccine can be ensured. The PRRSV inactivated vaccine prepared by using the method is high in antigen content, high in immunogenicity, high in antigen purity, good in security, small in side effect, free of adjuvant, rapid in antibody protection generation, easy to inject and easy to absorb.

The invention discloses preparation and application of a recombinant virus-like particle for surface display of African swine fever virus P30 and P72 proteins, a SpyTag tag protein is displayed on the surface of T7 bacteriophage through a T7 bacteriophage display technology, and therefore, engineered bacteriophage (T7-ST) is constructed. Meanwhile, through an escherichia coli prokaryotic expression system, a P30-Spycatcher fusion protein and a P72-Spycatcher fusion protein can be expressed and purified. In a proper buffer system, the T7-ST, the P30-SC fusion protein and the P72-SC fusion protein are mixed and incubated respectively, and finally, the recombinant VLP particle which carries out the surface play of the P30-SC protein and the P72-SC protein is obtained. The novel genetic engineering vaccine prepared by VLP has the characteristics of an outstanding immune protection effect, good safety, high antigen purity and the like, and multiple protection can be provided for the organism.

The invention discloses a reagent for hepatitis B virus antibody in-vitro diagnosis, the reagent comprises a solid phase antigen, an enzyme-labeled antigen and a chromogenic substrate, the solid phase antigen comprises a solid phase carrier and an antigen coated on the surface of the solid phase carrier, the enzyme-labeled antigen comprises an enzyme for labeling the antigen and an enzyme-labeled antigen, the antigen is hepatitis B antigen recombinant protein, the antigens in the solid-phase antigen and the enzyme-labeled antigen are the same hepatitis B antigen recombinant protein, the solid-phase carrier comprises magnetic microspheres, the enzyme comprises horse radish peroxidase, and the chromogenic substrate comprises TMB. The invention also discloses a method for preparing the reagent and a method for identifying the hepatitis B virus antibody by using the reagent. The reagent is used for detecting the hepatitis B virus antibody, has the advantages of good specificity, high sensitivity, accurate result, good repeatability and strong clinical applicability, and can accurately reflect the content index of the hepatitis B virus antibody in a human body.

The invention relates to a specific antigen polypeptide for a reticuloendotheliosis virus of poultry and application of the polypeptide. The amino acid sequence of the specific antigen polypeptide isSEQ ID No.5; the specific antigen polypeptide is coded by envelope protein gp90 gene of the virus, and has strong reactogenicity, the epitope of the antigen has good antibody reactivity, and can be used for specifically detecting the antibody of the REV, and the specific antigen polypeptide has the application value of clinical detection. The antibody for specifically resisting the REV can be prepared by utilizing a polypeptide antigen immune animal.